866-997-4948(US-Canada Toll Free)

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 58 Pages

Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Review, H2 2016, provides in depth analysis on Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1)
- The report reviews Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) Overview 7
Therapeutics Development 8
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Stage of Development 8
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Therapy Area 9
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Indication 10
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Products under Development by Companies 14
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 23
CanBas Co Ltd 23
Cascadian Therapeutics Inc 24
Eli Lilly and Company 25
Genentech Inc 26
ProNAi Therapeutics Inc 27
Sareum Holdings Plc 28
Vernalis Plc 29
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Drug Profiles 30
CBP-501 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
CCT-244747 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
FS-105 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GDC-0575 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ONT-2409 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
PNT-737 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
prexasertib - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SAR-020106 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecule to Inhibit Chk1 for Cancer - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecule to Inhibit CHK1 for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
V-158411 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Dormant Projects 46
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Discontinued Products 47
Serine/Threonine Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or Cell Cycle Checkpoint Kinase or CHEK1 or EC 2.7.11.1) - Featured News & Press Releases 48
Oct 05, 2016: Lilly To Present New Data on Prexasertib At ESMO 2016 48
Sep 22, 2016: New triple therapy could boost treatment and prevent relapse in head and neck cancer 48
May 23, 2016: Clinical Trials of CHK1 Inhibitor CCT245737 to Open at the Royal Marsden Hospital 49
Apr 19, 2016: Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016 50
Apr 05, 2016: CHK1 inhibitor CCT245737 Approved for Clinical Trials in Cancer Patients 51
Feb 01, 2016: CHK1 Clinical Trial Application Submissions 51
Dec 15, 2015: CHK1 Clinical Trial Applications 51
May 12, 2015: Sareum to Present at BioTrinity 2015 52
Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY2606368 at AACR Annual Meeting 2015 52
Apr 17, 2013: CanBas Announces Topline Results From Phase II Trial Of CBP501 In Patients With Non-Small Cell Lung Cancer 53
Jun 04, 2012: CanBas's CBP501 Meets Primary Endpoint In Phase II Study Of Malignant Pleural Mesothelioma 54
Jan 05, 2012: CanBas's CBP501 Receives Orphan Drug Designation From FDA For Malignant Mesothelioma 54
Nov 01, 2011: Canbas Enrolls Last Patient In Phase II Trial Of CBP501 As First-Line Treatment Of Malignant Pleural Mesothelioma 55
Oct 27, 2011: Canbas Announces Last Patient Enrolled In Phase II Trial Of CBP501 As First-Line Treatment Of Non-Small Cell Lung Cancer 55
Jan 20, 2010: New Molecules SAR-020106 Increase The Effectiveness Of Certain Cancer Therapies 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by CanBas Co Ltd, H2 2016 23
Pipeline by Cascadian Therapeutics Inc, H2 2016 24
Pipeline by Eli Lilly and Company, H2 2016 25
Pipeline by Genentech Inc, H2 2016 26
Pipeline by ProNAi Therapeutics Inc, H2 2016 27
Pipeline by Sareum Holdings Plc, H2 2016 28
Pipeline by Vernalis Plc, H2 2016 29
Dormant Projects, H2 2016 46
Discontinued Products, H2 2016 47

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *